CURRICULUM VITAE Gerald Louis Andriole, Jr., M.D. Address ...

Period: 2002-2009
Grant Title:
Complementary and Alternative Medicine for Urological Symptoms
Total Direct Costs: $305,412
Percent of Effort: 10%
Funding Agency:
National Institutes of Health/National Cancer Institute
Period: 2002-2007
Grant Title:
Survivor HRQOL and Spouse Satisfaction after Prostate Therapy
Total Direct Costs: $186,765
Percent of Effort: 4%
Funding Agency:
National Institute of Diabetes and Digestive and Kidney Diseases
(1 U01 DK82315-01)
Period: 2008-1013
Total Direct Cost: $3,944,192
Percent of Effort 10%
Other Support:
PAST
Funding Agency:
Winthrop Breon Laboratories
Period: 1987
Grant Title:
The Effect of Low Osmolar Contrast Media on the Interpretation
of Urinary Cytology Specimens
Funding Agency:
Merck, Sharp & Dohme Research Laboratories
Period: 1988-1997
Grant Title:
Safety, Tolerability and Efficacy of MK-906 (5-Alpha Reductase
Inhibitor) in Patients with Benign Prostatic Hyperplasia with Extension Studies
Mo13-24, Mo 25-36, Mo 37-48, Mo 49-60)
Funding Agency:
Merck, Sharp & Dohme Research Laboratories
Period: 1989-1992
Grant Title:
Effect of MK-906 on Stage D Prostate Cancer with Extension study
Funding Agency:
Pfizer, Inc.
Period: 1990
Grant Title:
Doxazosin Therapy for Men with BPH and Mild Hypertension
Funding Agency:
Merck, Sharp & Dohme Research Laboratories
Period: 1990
Grant Title:
Early Intervention Medical Therapy for BPH
Funding Agency:
ICI Pharmaceuticals
Period: 1990
Grant Title:
Casodex versus Castration for Men with Stage D2 Prostate Cancer
Funding Agency:
Merck, Sharp & Dohme Research Laboratories
Period: 1990-1997
Grant Title:
MK-906 Post Radical Prostatectomy Study with Five Open Label Extensions
5